Aberrant expression of microRNA-4443 (miR-4443) in human diseases

References

• Mohr AM, Mott JL. Overview of microRNA biology. Seminars in liver disease. 2015;35(1): 3–11.
   Google Scholar
• Cannell IG, Kong YW, Bushell M. How do microRNAs regulate gene expression? Biochem Soc Trans. 2008;36(6):1224–1231.
   PubMedGoogle Scholar
• Zhao Z, Sun W, Guo Z, et al. Mechanisms of lncRNA/microRNA interactions in angiogenesis. Life Sci. 2020;254:116900.
   PubMed Web of Science ®Google Scholar
• Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505(7483):344–352.
   PubMed Web of Science ®Google Scholar
• Mao M, Zhang J, Xiang Y, et al. Role of exosomal competitive endogenous RNA (ceRNA) in diagnosis and treatment of malignant tumors. Bioengineered. 2022;13(5):12156–12168.
   PubMed Web of Science ®Google Scholar
• Wang J, Wang J, Gu Q, et al. MiR-4443 promotes migration and invasion of breast cancer cells by inhibiting PEBP1 expression. Nan Fang Yi Ke Da Xue Xue Bao. 2020;40(12):1712–1719.
   PubMedGoogle Scholar
• Zhang W, Qiao B, Fan J. Overexpression of miR-4443 promotes the resistance of non-small cell lung cancer cells to epirubicin by targeting INPP4A and regulating the activation of JAK2/STAT3 pathway. Pharmazie. 2018;73(7):386–392.
   PubMed Web of Science ®Google Scholar
• Shefler I, Salamon P, Levi-Schaffer F, et al. MicroRNA-4443 regulates mast cell activation by T cell-derived microvesicles. J Allergy Clin Immunol. 2018;141(2132–41.e4):2132–2141.e4.
   PubMedGoogle Scholar
• Zuo XM, Sun HW, Fang H, et al. miR-4443 targets TRIM14 to suppress metastasis and energy metabolism of papillary thyroid carcinoma (PTC) in vitro. Cell Biol Int. 2021;45(9):1917–1925.
   PubMed Web of Science ®Google Scholar
• Meerson A, Yehuda H. Leptin and insulin up-regulate miR-4443 to suppress NCOA1 and TRAF4, and decrease the invasiveness of human colon cancer cells. BMC Cancer. 2016;16(1):882.
   PubMedGoogle Scholar
• Zhou C, Xu J, Lin J, et al. Long noncoding RNA FEZF1-AS1 promotes osteosarcoma progression by regulating the miR-4443/NUPR1 axis. Oncol Res. 2018;26(9):1335–1343.
   PubMed Web of Science ®Google Scholar
• Gong J, Wang J, Liu T, et al. lncRNA FEZF1‑AS1 contributes to cell proliferation, migration and invasion by sponging miR‑4443 in hepatocellular carcinoma. Mol Med Rep. 2018;18(6):5614–5620.
   PubMed Web of Science ®Google Scholar
• Gao Y, Xu Y, Wang J, et al. lncRNA MNX1-AS1 promotes glioblastoma progression through inhibition of miR-4443. Oncol Res. 2019;27(3):341–347.
   PubMed Web of Science ®Google Scholar
• Li M, Zhang X, Ding X; Li M, Zhang X, Ding X, Zheng Y, Du H, Li H, et al. Long noncoding RNA LINC00460 promotes cell progression by sponging miR-4443 in head and neck squamous cell carcinoma. Cell Transplant. 2020;29:963689720927405.
   PubMed Web of Science ®Google Scholar
• Li S, Lu G, Wang D, et al. MicroRNA-4443 regulates monocyte activation by targeting tumor necrosis factor receptor associated factor 4 in stroke-induced immunosuppression. Eur J Neurol. 2020;27(8):1625–1637.
   PubMed Web of Science ®Google Scholar
• Xiao J, Zhang Y, Tang Y, et al. hsa-miR-4443 inhibits myocardial fibroblast proliferation by targeting THBS1 to regulate TGF-β1/α-SMA/collagen signaling in atrial fibrillation. Braz J Med Biol Res = Rev Bras Pesqui Med Biol. 2021;54(4):e10692.
   PubMed Web of Science ®Google Scholar
• Qi Y, Zhou Y, Chen X, et al. MicroRNA-4443 causes CD4+ T cells dysfunction by targeting TNFR-associated factor 4 in graves’ disease. Front Immunol. 2017;8:1440.
   PubMed Web of Science ®Google Scholar
• Qi X, Zhang DH, Wu N, et al. ceRNA in cancer: possible functions and clinical implications. J Med Genet. 2015;52(10):710–718.
   PubMed Web of Science ®Google Scholar
• McNamara KB, Wedell N, Simmons LW. Experimental evolution reveals trade-offs between mating and immunity. Biol Lett. 2013;9(4):20130262.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang Q, Wang D, et al. Microenvironment-induced TIMP2 loss by cancer-secreted exosomal miR-4443 promotes liver metastasis of breast cancer. J Cell Physiol. 2020;235(7–8):5722–5735.
   PubMed Web of Science ®Google Scholar
• Zhao X, Tang D, Chen X, et al. Functional lncRNA-miRNA-mRNA networks in response to baicalein treatment in hepatocellular carcinoma. Biomed Res Int. 2021;2021:8844261.
   PubMed Web of Science ®Google Scholar
• Díaz-Coránguez M, Liu X, Antonetti DA. Tight junctions in cell proliferation. Int J Mol Sci. 2019;20(23):5972.
   Web of Science ®Google Scholar
• Vollmann-Zwerenz A, Leidgens V, Feliciello G, et al. Tumor cell invasion in glioblastoma. Int J Mol Sci. 2020;21(6):1932.
   Google Scholar
• Yoshikawa T, Miyamoto M, Aoyama T, et al. JAK2/STAT3 pathway as a therapeutic target in ovarian cancers. Oncol Lett. 2018;15(4):5772–5780.
   PubMed Web of Science ®Google Scholar
• Saadat S, Noureddini M, Mahjoubin-Tehran M, et al. Pivotal role of TGF-β/Smad signaling in cardiac fibrosis: non-coding RNAs as effectual players. Front Cardiovasc Med. 2020;7:588347.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Chilton E, Raman J, et al. Are interactions between epicardial adipose tissue, cardiac fibroblasts and cardiac myocytes instrumental in atrial fibrosis and atrial fibrillation? Cells. 2021;10.
   Google Scholar
• Dorrington MG, Idc F. NF-κB signaling in macrophages: dynamics, crosstalk, and signal integration. Front Immunol. 2019;10:705.
   PubMed Web of Science ®Google Scholar
• Masliah-Planchon J, Garinet S, Pasmant E. RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action. Oncotarget. 2016;7(25):38892–38907.
   PubMedGoogle Scholar
• Komi DEA, Redegeld FA. Role of mast cells in shaping the tumor microenvironment. Clin Rev Allergy Immunol. 2020;58(3):313–325.
   PubMed Web of Science ®Google Scholar
• Hong H, Tian XY. the role of macrophages in vascular repair and regeneration after ischemic injury. Int J Mol Sci. 2020;21(17):6328.
   Web of Science ®Google Scholar
• Meador CB, Hata AN. Acquired resistance to targeted therapies in NSCLC: updates and evolving insights. Pharmacol Ther. 2020;210:107522.
   PubMed Web of Science ®Google Scholar
• Plosker GL, Faulds D. EpirubicinA review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 1993;45(5):788–856.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhong SL, Lu P, et al. miR-4443 participates in the malignancy of breast cancer. PloS one. 2016;11(8):e0160780.
   PubMed Web of Science ®Google Scholar
• Guo J, Xu B, Han Q, et al. Ferroptosis: a novel anti-tumor action for cisplatin. Cancer Res Treat. 2018;50(2):445–460.
   PubMed Web of Science ®Google Scholar
• Qin X, Yu S, Xu X, et al. Comparative analysis of microRNA expression profiles between A549, A549/DDP and their respective exosomes. Oncotarget. 2017;8(26):42125–42135.
   PubMedGoogle Scholar
• Song Z, Jia G, Ma P, et al. Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis. Life Sci. 2021;276:119399.
   PubMed Web of Science ®Google Scholar
• Wang J, Liu L. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A. J Ovarian Res. 2021;14(1):165.
   PubMed Web of Science ®Google Scholar
• Zhang X, Huang T, Li Y, et al. Upregulation of THBS1 is related to immunity and chemotherapy resistance in gastric cancer. Int J Gen Med. 2021;14:4945–4957.
   PubMed Web of Science ®Google Scholar
• He N, Xiang L, Chen L, et al. The role of long non-coding RNA FGD5-AS1 in cancer. Bioengineered. 2022;13(4):11026–11041.
   PubMed Web of Science ®Google Scholar
• Drusco A, Fadda P, Nigita G, et al. Circulating micrornas predict survival of patients with tumors of glial origin. EBioMedicine. 2018;30:105–112.
   PubMed Web of Science ®Google Scholar
• Chen W, Guo Z, Wu J, et al. Identification of a ZC3H12D-regulated competing endogenous RNA network for prognosis of lung adenocarcinoma at single-cell level. BMC Cancer. 2022;22(1):115
   PubMed Web of Science ®Google Scholar